Genincode PLC
F:9PL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Genincode PLC
F:9PL
|
UK |
|
E
|
Erlebnis Akademie AG
XMUN:EAD
|
DE |
|
S
|
Sumitomo Realty & Development Co Ltd
DUS:RL2
|
JP |
|
V
|
Vilkyskiu Pienine AB
XMUN:UDW
|
LT |
|
RS Group PLC
F:ECN
|
UK |
|
Abeona Therapeutics Inc
F:PCJ
|
US |
|
P
|
Pitney Bowes Inc
DUS:PBW
|
US |
|
C
|
Computacenter PLC
F:COUD
|
UK |
|
Utah Medical Products Inc
F:UTM
|
US |
Intrinsic Value
Is 9PL undervalued or overvalued?
See the intrinsic value estimate for Genincode PLC and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Genincode Does
GeninCode PLC develops and sells genetic tests that help doctors assess a patient’s inherited risk of cardiovascular disease. Its main products use DNA markers and clinical data to estimate the chance of problems such as coronary artery disease and to support earlier prevention decisions. The company focuses on turning genetic information into practical reports that physicians can use in everyday care.
- Headquarters
- United Kingdom UK
- Employees
- 36
- IPO date
- Jul 22, 2021
Earnings Waterfall
Genincode PLC
The intrinsic value for Genincode PLC (9PL) under the Base Case is hidden EUR.
Compared with the current market price of 0.006 EUR, the stock appears hidden.